| abstract |
The present invention provides a combination comprising (a) a sulfonylurea; and (b) at least one of the following components: (i) an insulin modulator and (ii) an aldosterone antagonist, eg, a combination comprising (a) a glyburide Benurea, or a structural or functional analog thereof; and (b) at least one of the following components: (i) exenatide, or a structural or functional analog thereof, or a pharmaceutically acceptable salt thereof; and (ii) canrenoic acid Potassium or its structural or functional analogs. The combination is suitable for the treatment of stroke and other neurodegenerative disorders, and for the treatment and/or prevention of ischemia and/or reperfusion injury in various vital organs including the brain and heart. Other aspects of the present invention relate to pharmaceutical products and pharmaceutical compositions comprising said combinations according to the present invention, and methods of treatment using them. |